Shanghai Pharmaceuticals expects significant profit increase in interim results

Shanghai Pharmaceuticals Holding Co. anticipates a significant improvement in its interim results for the first half of 2025. The company projects a net profit attributable to owners of the parent company of RMB4,450 million, a RMB1,508 million increase, or approximately 52% year-on-year increase. This increase is partly attributed to the completed acquisition of an additional 10% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) in April. This acquisition resulted in the company's total equity interest in SHPL increasing from 50% to 60% and subsequent consolidation of SHPL's financial results. The company's previous year net profit was RMB2,942 million, with earnings per share of RMB0.79. Shareholders and potential investors are advised to exercise caution.